Estrogen receptors α and β have similar activities in multiple endothelial cell pathways

Endocrinology

Volumn 143, Issue 10, 2002, Pages 3785-3795

  Evans, Mark J ^a   Harris, Heather A ^b   Miller, Chris P ^b   Karathanasis, Sotirios K ^b   Adelman, Steven J ^a,b  

^a Women's Health Research Institute   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA THIOPHENYLESTRADIOL; ADENOVIRUS VECTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; ESTRADIOL; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INTERLEUKIN 1BETA; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN LYSINE 6 OXIDASE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

AORTA; ARTICLE; CARDIOVASCULAR DISEASE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENDOTHELIUM CELL; ESTROGEN ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WESTERN BLOTTING;

AMINO ACID SEQUENCE; BASE SEQUENCE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEINS; RECEPTORS, ESTROGEN; UMBILICAL VEINS;

EID: 0036773514     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2002-220356     Document Type: Article

References (69)

1. Eberhardt MS, Ingram DD, Makuc DM 2001 Health, United States, 2001. Hyattsville, MD: National Center for Health Statistics; 166
2. Samsioe G 1994 Cardioprotection by estrogens: Implications of observational studies. Int J Fertil Menopausal Studies 39:20-27
3. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ 2000 A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 133:933-941
4. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 280:605-613
5. The Writing Group for the PEPI Trial 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208
6. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, Waters D 2000 Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343:522-529
7. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, Waclawiw M, Fineberg SE 1997 The Postmenopausal Estrogen/Progestin Interventions Study: Primary outcomes in adherent women. Maturitas 27:261-274
8. Darling GM, Johns JA, McCloud PI, Davis SR 1997 Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 337:595-601
9. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J 1999 Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418
10. The BIP Study Group 2000 Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) Study. Circulation 102:21-27
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto Jr AM 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279:1615-1622
12. Godsland IF 2001 Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein(a) concentrations: Analysis of studies published from 1974-2000. Fertil Steril 75:898-915
13. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, Levy RI, Hulley SB 2000 Estrogen and progestirt, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA 283:1845-1852
14. Danesh J, Collins R, Peto R 2000 Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102:1082-1085
15. Stein JH, Rosenson RS 1997 Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 157:1170-1176
16. Vehkavaara S, Hakala-Ala-Pietila T, Virkamaki A, Bergholm R, Ehnholm C, Hovatta O, Taskinen MR, Yki-Jarvinen H 2000 Differential effects of oral and transdermal estrogen replacement therapy on endothelial function in postmenopausal women. Circulation 102:2687-2693
17. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL 1986 Biologic effects of transdermal estradiol. N Engl J Med 314:1615-1620
18. Clarkson T, Anthony M 1997 Effects on the Cardiovascular System: Basic Aspects. Philadelphia: Lippincott-Raven; 89-118
19. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI 2000 The NF-κB signal transduction pathway in aortic endothelial cells is primed for activation in regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci USA 97:9052-9057
20. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D 1996 Activated transcription factor nuclear factor-κB is present in the atherosclerotic lesion. J Clin Invest 97:1715-1722
21. Van Baal WM, Emeis JJ, Kenemans P, Kessel H, Peters-Muller ER, Schalkwijk CG, van der Mooren MJ, Stehouwer CD 1999 Short-term hormone replacement therapy: Reduced plasma levels of soluble adhesion molecules. Eur J Clin Invest 29:913-921
22. Koh KK, Blum A, Hathaway L, Mincemoyer R, Csako G, Waclawiw MA, Panza JA, Cannon III RO 1999 Vascular effects of estrogen and vitamin E therapies in postmenopausal women. Circulation 100:1851-1857
23. Koh KK, Cardillo C, Bui MN, Hathaway L, Csako G, Waclawiw MA, Panza JA, Cannon III RO 1999 Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 99:354-360
24. Cushman M, Legault C, Barrett-Connor E, Stefanick ML, Kessler C, Judd HL, Sakkinen PA, Tracy RP 1999 Effect of postmenopausal hormones on inflammation-sensitive proteins: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Study. Circulation 100:717-722
25. Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC 2001 Reciprocal antagonism between estrogen receptor and NF-κB activity in vivo. Circ Res 89:823-830
26. Bourassa PA, Milos PM, Gaynor BJ, Breslow JL, Aiello RJ 1996 Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 93:10022-10027
27. Caulin-Glaser T, Watson CA, Pardi R, Bender JR 1996 Effects of 17β-estradiol on cytokine-induced endothelial cell adhesion molecule expression. J Clin Invest 98:36-42
28. Davies MJ 2001 Going from immutable to mutable atherosclerotic plaques. Am J Cardiol 88:2F-9F
29. Best PJ, Berger PB, Miller VM, Lerman A 1998 The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 128:285-288
30. Webb CM, Ghatei MA, McNeill JG, Collins P 2000 17β-Estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 102:1617-1622
31. Haenggi W, Bersinger NA, Mueller MD, Birkhaeuser MH 1999 Decrease of serum endothelin levels with postmenopausal hormone replacement therapy or tibolone. Gynecol Endocrinol 13:202-205
32. Schiffrin EL, Intengan HD, Thibault G, Touyz RM 1997 Clinical significance of endothelin in cardiovascular disease. Curr Opin Cardiol 12:354-367
33. Morey AK, Razandi M, Pedram A, Hu RM, Prins BA, Levin ER 1998 Oestrogen and progesterone inhibit the stimulated production of endothelin-1. Biochem J 330:1097-1105
34. Holm P, Stender S, Andersen HO, Hansen BF, Nordestgaard BG 1997 Antiatherogenic effect of estrogen abolished by balloon catheter injury in cholesterol-clamped rabbits. Arterioscler Thromb Vasc Biol 17:1504-1511
35. Makela S, Savolainen H, Aavik E, Myllarniemi M, Strauss L, Taskinen E, Gustafsson JA, Hayry P 1999 Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors α and β. Proc Natl Acad Sci USA 96:7077-7082
36. Lindner V, Kim SK, Karas RH, Kuiper GG, Gustafsson JA, Mendelsohn ME 1998 Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 83:224-229
37. Sullivan Jr TR, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell Jr TF, Mendelsohn ME 1995 Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96:2482-2488
38. Karas RH, Hodgin JB, Kwoun M, Krege JH, Aronovitz M, Mackey W, Gustafsson JA, Korach KS, Smithies O, Mendelsohn ME 1999 Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci USA 96:15133-15136
39. Iafrati MD, Karas RH, Aronovitz M, Kim S, Sullivan Jr TR, Lubahn DB, O'Donnell Jr TF, Korach KS, Mendelsohn ME 1997 Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med 3:545-548
40. Karas RH, Schulten H, Pare G, Aronovitz MJ, Ohlsson C, Gustafsson JA, Mendelsohn ME 2001 Effects of estrogen on the vascular injury response in estrogen receptor α, β (double) knockout mice. Circ Res 89:534-539
41. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA 1997 Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870
42. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263
43. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ, Scanlan TS 1997 Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 277:1508-1510
44. Jones PS, Parrott E, White INH 1999 Activation of Transcription by Estrogen Receptor α and β is cell type- and promoter-dependent. J Biol Chem 274:32008-32014
45. Bhat RA, Harnish DC, Stevis PE, Lyttle CR, Komm BS 1998 A novel human estrogen receptor β: Identification and functional analysis of additional N-terminal amino acids. J Steroid Biochem Mol Biol 67:233-240
46. Harnish DC, Evans MJ, Scicchitano MS, Bhat RA, Karathanasis SK 1998 Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing. J Biol Chem 273:9270-9278
47. Hsu KH, Friedman H 1983 Dimethyl sulfoxide-induced transglutaminase activity in murine-derived Friend erythroleukemia cells. J Natl Cancer Inst 70:965-969
48. Harnish DC, Scicchitano MS, Adelman SJ, Lyttle CR, Karathanasis SK 2000 The role of CBP in estrogen receptor cross-talk with nuclear factor-κB in HepG2 cells. Endocrinology 141:3403-3411
49. Akishita M, Ouchi Y, Miyoshi H, Orimo A, Kozaki K, Eto M, Ishikawa M, Kim S, Toba K, Orimo H 1996 Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 125:27-38
50. Ito H, Akiyama H, Iguchi H, Iyama K, Miyamoto M, Ohsawa K, Nakamura T 2001 Molecular cloning and biological activity of a novel lysyl oxidase-related gene expressed in cartilage. J Biol Chem 276:24023-24029
51. Driscoll MD, Sathya G, Muyan M, Klinge CM, Hilf R, Bambara RA 1998 Sequence requirements for estrogen receptor binding to estrogen response elements. J Biol Chem 273:29321-29330
52. Mendelsohn ME, Karas RH 1999 The protective effects of estrogen on the cardiovascular system. N Engl J Med 340:1801-1811
53. Read MA, Whitley MZ, Gupta S, Pierce JW, Best J, Davis RJ, Collins T 1997 Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-κB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem 272:2753-2761
54. Min W, Pober JS 1997 TNF initiates E-selectin transcription in human endothelial cells through parallel TRAF-NF-κB and TRAF-RAC/CDC42-JNK-c-Jun/ATF2 pathways. J Immunol 159:3508-3518
55. Brostjan C, Anrather J, Csizmadia V, Natarajan G, Winkler H 1997 Glucocorticoids inhibit E-selectin expression by targeting NF-κB and not ATF/c-Jun. J Immunol 158:3836-3844
56. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D, Hodgin J, Shaul PW, Thoren P, Smithies O, Gustafsson JA, Mendelsohn ME 2002 Abnormal vascular function and hypertension in mice deficient in estrogen receptor β. Science 295:505-508
57. Ogawa S, Emi M, Shiraki M, Hosoi T, Ouchi Y, Inoue S 2000 Association of estrogen receptor beta (ESR2) gene polymorphism with blood pressure. J Hum Genet 45:327-330
58. Lehrer S, Rabin J, Kalir T, Schachter BS 1993 Estrogen receptor variant and hypertension in women. Hypertension 21:439-441
59. Wilmink AB, Quick CR 1998 Epidemiology and potential for prevention of abdominal aortic aneurysm. Br J Surg 85:155-162
60. Kojima S, Nara K, Rifkin DB 1993 Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Biol 121:439-448
61. Grainger DJ,Witchell CM, Metcalfe JC 1995 Tamoxifen elevates transforming growth factor-β and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med 1:1067-1073
62. Miller CP, Jirkovsky I, Tran BD, Harris HA, Moran RA, Komm BS 2000 Synthesis and estrogenic activities of novel 7-thiosubstituted estratriene derivatives. Bioorgan Med Chem Lett 10:147-151
63. Sun J, Meyers MJ, Fink BE, Rajendran R, Katzenellenbogen JA, Katzenellenbogen BS 1999 Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-α or estrogen receptor-β. Endocrinology 140:800-804
64. Gaido KW, Leonard LS, Maness SC, Hall JM, McDonnell DP, Saville B, Safe S 1999 Differential interaction of the methoxychlor metabolite 2, 2-bis-(p-hydroxyphenyl)-1,1,1-trichloroethane with estrogen receptors α and β. Endocrinology 140:5746-5753
65. Evans MJ, Lai K, Shaw LJ, Hamish DJ, Chadwick CC 2002 Estrogen receptor α inhibits IL-1β induction of gene expression in the mouse liver. Endocrinology 143:2559-2570
66. Maness SC, McDonnell DP, Gaido KW 1998 Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells. Toxicol Appl Pharmacol 151:135-142
67. Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M 1997 Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389:753-758
68. Wakeling AE, Bowler J 1992 ICI 182, 780, a new antioestrogen with clinical potential. J Steroid Biochem Mol Biol 43:173-177
69. Shiau AK, Barstad D, Radek JT, Meyers MJ, Nettles KW, Katzenellenbogen BS, Katzenellenbogen JA, Agard DA, Greene GL 2002 Structural characterization of a subtype-selective ligand reveals a novel mode of estrogen receptor antagonism. Nat Struct Biol 9:359-364